Blog

Head and neck cancer (HNC) remains a significant health concern, but the landscape is shifting thanks to precision medicine. This revolutionary approach moves beyond a "one-size-fits-all" strategy by analyzing the unique genetic makeup of your tumor to tailor treatment plans. Here's how precision medicine is transforming HNC treatment during Head and Neck Cancer Awareness Month:

Head and neck cancer (HNC) can encompass various cancers affecting the throat, mouth, voice box, and surrounding areas. While it may sound serious, it's important to remember that significant progress is being made in treatment, especially with the rise of personalized medicine. Here's a breakdown of HNC and how personalized medicine is changing the game

Cracking the HRD Code: Why Genomic Test Companies are Key to Unlocking Precision Cancer Care

Abstract: Tinengotinib, a next-generation FGFR1-3 inhibitor, has exhibited promising efficacy in cholangiocarcinoma patients with FGFR2 fusion who have undergone prior treatment with other FGFR inhibitors, as well as in patients with other FGFR alterations (non-fusion). These recent findings were presented at the 2024 ASCO Gastrointestinal Cancers Symposium.

Colorectal cancer (CRC) remains a significant health concern, but advancements in precision medicine offer a ray of hope. The treatment approach moves beyond a "one-size-fits-all" strategy by analyzing your tumor's unique genetic makeup to tailor treatment plans. Here's what you should know about colorectal cancer and how genomic testing empowers precision medicine:

Abstract: The NRG-GI005 study is the largest study to date to evaluate the role of ctDNA in guiding colon cancer treatment. The results suggest that the clinical application of ctDNA testing after surgery in low-risk stage IIA colon cancer remains unclear.

US FDA updates, Taiwan FDA updates, and Taiwan NHI updates

Abstract: A poster presented at the 2024 Genitourinary Cancers Symposium highlighted the underutilization of homologous recombination repair (HRR) gene testing for potential targeted therapy with PARP inhibitors in real-world studies of mCRPC patients in the US.

Imagine a powerful tool capable of identifying cancer patients who might benefit from specific, targeted treatments. This tool, the Homologous Recombination Deficiency (HRD) biomarker, holds immense promise in personalized cancer care. However, a major hurdle stands in the way – the lack of standardized methods for measuring and reporting HRD. This inconsistency leads to confusion and hinders the full potential of this valuable biomarker.

Ovarian cancer, while less common than other cancers, remains a significant threat to women's health. But amidst the challenges, a new beacon of hope emerges: Homologous Recombination Deficiency (HRD). This complex biological marker is transforming the way we understand and treat ovarian cancer, offering personalized approaches and improved outcomes. So, let's delve into the world of ovarian cancer and unravel the fascinating connection with HRD

The discovery of Homologous Recombination Deficiency (HRD) has significantly impacted the landscape of ovarian cancer treatment. This intricate biological marker is no longer just genomic information but a key player in unlocking personalized treatment strategies and offering new hope for patients. Let's explore the diverse applications of HRD in ovarian cancer.

Deciphering the Code: Demystifying HRD as a Key Biomarker in Ovarian Cancer.

Cancer genomic profiling tests look for genetic mutations in the tumor of cancer patients. This helps physicians identify suitable treatment based on the features of the cancer cells at a molecular level. This approach is sometimes referred to as tumor profiling, precision medicine, or personalized medicine.

The ATTLAS phase III trials demonstrated that quadruple therapy, consisting of chemoimmunotherapy combined with an antiangiogenic agent, can extend progression-free survival (PFS) in patients with EGFR- or ALK-mutated non-small cell lung cancer (NSCLC) progressing on TKIs.

Based on results from a phase 3, randomized PAPILLON trial presented at the 2023 ESMO Congress, amivantamab plus chemotherapy is recommended for treatment-naïve, locally advanced, or metastatic NSCLC patients diagnosed with EGFR exon 20 insertion (EGFR ex20ins) mutation. Amivantamab-Chemotherapy demonstrated significant clinical benefits over standard-of-care, and the latest NCCN guidelines recommend this regimen for frontline EGFR ex20ins.

Abstract: Acquired ESR1 co-alterations, such as RB1, FGFR1, CCND1, ERBB2, TP53, and CCNE1, often occurred in HR+/HER2- breast cancer after endocrine therapy (ET). According to an analysis of the phase 2 ELAINE 2 study, these ESR1 co-alterations didn’t impact the combination of lasofoxifene and abemaciclib efficacy in ESR1+ metastatic breast cancer (mBC). These results were published in 2023 San Antonio Breast Cancer Symposium.

The fight against cancer is a daunting challenge. We seek to use our expertise and experience to support those who are undertaking this battle.

As reported in the 2023 ESMO annual conference, Selpercatinib demonstrated superior clinical benefit compared to cabozantinib or vandetanib in a phase 3 LIBRETTO-531 study for RET-mutant medullary thyroid cancer (MTC).

destiny-pantumor02-the-adc-trastuzumab-deruxtecan-t-dxd-showed-activity-in-her2-expressing-solid-tumors

The MOUNTAINEER study, as presented at the 2023 ASCO and ESMO annual meetings, provides an update on the detection of HER2 amplification in mCRC patients using blood NGS and tissue assays. Patients in whom HER2 amplification is not initially detected by blood NGS may be identified through tissue-based assays, suggesting a potential benefit from HER2-directed therapy. In the study, HER2 amplification detected by tissue assays demonstrated a high percentage agreement and showed a clinical benefit trend in patients with RAS wild-type HER2+ unresectable or metastatic colorectal cancer (mCRC) treated with tucatinib in combination with trastuzumab. Exploratory biomarker analyses revealed that many patients exhibited multiple heterogeneous resistance alterations, including PIK3CA, EGFR, and MET alterations in disease progression.

Learning to face death teaches you how to truly live.

While fighting ovarian cancer for 18 years, Ms. Chang underwent several rounds of chemotherapy and surgery.

Fighting cancer successfully is possible with the support and love from family.

Cancer has completely changed my perspective on life.

To date I have done three rounds of ACTMonitor profiling to monitor the mutations of my liver tumor semi-annually.